InflaRx is cutting approximately 30% of its employees in a bid to streamline its spending and pour more of its resources into its lead candidate. To accompany the layoffs, InflaRx will also pull money from its investigational antibody Gohibic, according to a press announcement Jan. 8.
All entries for: Infectious Diseases
November 13, 2025
Spero Therapeutics, Inc.
Neutral Outlook
Cambridge, Massachusetts,
1-50 employees
Further, in August 2022, President Biden signed into the law the Inflation Reduction Act (“IRA”). Among other things, the IRA has multiple provisions that may impact the prices of drug products that are both sold into the Medicare program and throughout the United States. A manufacturer of drugs covered by Medicare Parts B or D must now pay a rebate to the federal government if their drug product’s price increases faster than the rate of inflation. This calculation is made on a drug product by drug product basis and the amount of the rebate owed to the federal government is directly dependent on the volume of a drug product that is paid for by Medicare Parts B or D.
Disease Area: Infectious Diseases, Rare Diseases
Drug Type: Small Molecule
November 6, 2025
Cidara Therapeutics, Inc.
Neutral Outlook
San Diego, CA
1-50 employees
For example, on August 16, 2022, the Inflation Reduction Act of 2022, or IRA, was signed into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in Affordable Care Act marketplaces through plan year 2025. The IRA also eliminates the “donut hole” under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and through a newly established manufacturer discount program
Disease Area: Infectious Diseases, Oncology, Respiratory Diseases
Drug Type: Biologic
November 5, 2025
ImmunityBio, Inc.
Neutral Outlook
" Woburn, MA"
501-1,000 employees
As discussed above, in August 2022, Congress passed the IRA, which includes prescription drug provisions that have significant implications for the pharmaceutical industry and Medicare beneficiaries, including allowing the federal government to negotiate a maximum fair price for certain high-priced single source Medicare drugs, imposing penalties and excise tax for manufacturers that fail to comply with the drug price negotiation requirements, requiring inflation rebates for all Medicare Part B and Part D drugs, with limited exceptions, if their drug prices increase faster than inflation, and redesigning Medicare Part D to reduce out-of-pocket prescription drug costs for beneficiaries, among other changes. Various stakeholders have initiated lawsuits against the federal government asserting that the price negotiation provisions of the IRA are unconstitutional.
Disease Area: Infectious Diseases, Multiple, Oncology
Drug Type: Biologic, Small Molecule
November 5, 2025
Vir Biotechnology, Inc
Neutral Outlook
San Francisco, CA
201-500 employees
It is currently unclear how certain new measures, including the drug pricing provisions of the Inflation Reduction Act of 2022 (and subsequent rulemaking) and changes to Medicaid eligibility requirements in the OBBBA, will ultimately be effectuated. Accordingly, we cannot predict with certainty what impact these or any other federal or state health reforms will have on us, including whether finalized rules will be implemented or withstand judicial review.
Disease Area: Antiviral, Chronic Disease, Immune Diseases, Infectious Diseases, Oncology
Drug Type: Biologic
September 23, 2025
Seres Therapeutics
Layoffs
Cambridge, MA
51-200 employees
As part of cost-cutting measures to support its lead program, Seres Therapeutics is laying off about 25% of its workforce, which includes people let go effective in August.Seres expects the cuts will help extend its cash runway into the second quarter of 2026.
Disease Area: Immune Diseases, Infectious Diseases, Oncology
Drug Type: Biologic
August 8, 2025
Precision BioSciences
Layoffs
Durham, NC
51-200 employees
Delaware-based Precision BioSciences has terminated an undisclosed number of employees in order to extend its cash runway into the second half of 2027.
Disease Area: Chronic Disease, Hematology, Infectious Diseases, Multiple, Neurological Diseases, Rare Diseases
Drug Type: Biologic
July 8, 2025
CSL Limited
Layoffs
Pasadena, CA
10,001-50,000 employees
The Australian multinational biotech CSL is consolidating its research and development team, according to reporting from Fierce Biotech. The number of employees affected by the consolidation is unclear, though CSL said that more details would be shared at the company’s annual earnings call in August. According to comments made to Fierce, CSL will increasingly rely on external partnerships to bolster its pipeline. The reorganization comes just a month after the company got approval from the FDA for a preventive for attacks in patients with hereditary angioedema.
Disease Area: Hematology, Infectious Diseases, Multiple, Rare Diseases
Drug Type: Biologic, Small Molecule
June 16, 2025
ImmunityBio
Layoffs
Woburn, MA
501-1,000 employees
The San Diego–based biotech is letting go of three employees at their Woburn, Massachusetts, effective from July 29 to Aug. 12, according to a Worker Adjustment and Retraining Notification notice.
Disease Area: Infectious Diseases, Multiple, Oncology
Drug Type: Biologic, Small Molecule
May 13, 2025
AN2 Therapeutics
Negative Outlook
Menlo Park, CA
1-50 employees
It is currently unclear how the IRA will be implemented but is likely to have a significant impact on the pharmaceutical industry. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.
Disease Area: Infectious Diseases, Multiple, Oncology, Respiratory Diseases
Drug Type: Small Molecule